Prostatitis

Summary

Prostatitis (MONDO:0005280) is a disease (an umbrella term covering 5 Mondo subtypes) with 11 GWAS associations across 25 studies and 31 clinical trials. Top therapeutic interventions include levofloxacin anhydrous, ofloxacin, and tolterodine. A subtype of prostate disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Umbrella term: 5 Mondo subtypes
• GWAS associations: 11
• Clinical trials: 31

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	prostatitis
Mondo ID	MONDO:0005280
EFO	EFO:0003830
MeSH	D011472
DOID	DOID:14654
NCIT	C26866
SNOMED CT	9713002
UMLS	C0033581
MedGen	10965
Is cancer (heuristic)	no

Also known as: inflammation of prostate gland · prostate gland inflammation · prostatitis · prostatitis (disease)

Data availability: 11 GWAS associations (25 studies) · 1 HPO phenotype.

Disease family

This is a subtype of prostate disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › reproductive system disorder › male reproductive system disorder › prostate disorder › prostatitis

Related subtypes (4): prostatic cyst, prostate calculus, benign prostatic hyperplasia, prostate neoplasm

Subtypes (5): prostatocystitis, granulomatous prostatitis, gonococcal prostatitis, chronic prostatitis, Trichomonas prostatitis

Genetics & variants

GWAS landscape

11 GWAS associations across 25 studies. Top hits map to 5 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs568184630	4e-12	PXDN - MYT1L	C	2.68
rs186428442	8e-12	MIR548BAHG - RPL7P13	C	2.06
rs62113214	1e-11	KLK3	T	0.31
rs17632542	2e-11	KLK3	T	0.32
rs187571212	2e-11	LINC01163	C	1.99
rs147158059	2e-11	Metazoa_SRP - TMCO5A	A	2.73
rs117052033	5e-11	HNF1B - YWHAEP7	?
rs377025887	8e-09	NPSR1-AS1	?
rs62199052	3e-08	TEX44 - RN7SL499P	C	1.8
rs9885256	6e-08	LINC02997	?
rs35585020	4e-07	LINC01169	?

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90478614	Verma A	2024	19,654	375,746	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90478613	Verma A	2024	7,247	90,032	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90480905	Verma A	2024	7,247	90,032	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90476155	Verma A	2024	4,320	407,658	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90129456	Zorina-Lichtenwalter K	2023	3,604	199,950	Genetic risk shared across 24 chronic pain conditions: identification and characterization with genomic structural equation modeling.
GCST90478612	Verma A	2024	3,101	47,376	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90652125	Liu TY	2025	2,298	84,916	Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population.
GCST90080620	Backman JD	2021	2,279	172,873	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90084606	Backman JD	2021	2,279	172,873	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90478618	Verma A	2024	1,997	410,015	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	1
Tier 2: splice/UTR	0
Tier 3: regulatory	0
Tier 4: intronic/intergenic	10

MAF distribution

Bucket	Variants
common (>=0.05)	5
low_freq (0.01-0.05)	0
rare (<0.01)	4
unknown	2

Functional consequences

Consequence	Count
intron_variant	6
intergenic_variant	4
missense_variant	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs568184630	2	1747872	C>T	0	intron_variant	PXDN - MYT1L	4e-12	Tier 4: intronic/intergenic
rs186428442	2	49454172	C>G,T	0.001	intergenic_variant	MIR548BAHG - RPL7P13	8e-12	Tier 4: intronic/intergenic
rs62113214	19	50859281	T>G	0.06	intron_variant	KLK3	1e-11	Tier 4: intronic/intergenic
rs17632542	19	50858501	T>C	0.075	missense_variant	KLK3	2e-11	Tier 1: coding
rs187571212	10	128229257	C>G	0.001	intron_variant	LINC01163	2e-11	Tier 4: intronic/intergenic
rs147158059	15	37243617	A>G	0.001	intergenic_variant	Metazoa_SRP - TMCO5A	2e-11	Tier 4: intronic/intergenic
rs117052033	17	37779141	C>A,T		intron_variant	HNF1B - YWHAEP7	5e-11	Tier 4: intronic/intergenic
rs377025887	7	34309560	C>A		intergenic_variant	NPSR1-AS1	8e-09	Tier 4: intronic/intergenic
rs62199052	2	231609605	G>C,T	0.371	intergenic_variant	TEX44 - RN7SL499P	3e-08	Tier 4: intronic/intergenic
rs9885256	5	67568092	A>G,T	0.05	intron_variant	LINC02997	6e-08	Tier 4: intronic/intergenic
rs35585020	15	66683451	G>GC	0.05	intron_variant	LINC01169	4e-07	Tier 4: intronic/intergenic

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

1 approved, 3 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Ciprofloxacin	Approved (phase 4)
Alfuzosin	Phase 3 (in late-stage trials)
Onabotulinumtoxina	Phase 3 (in late-stage trials)
Pregabalin	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Apremilast, Dutasteride, Pentosan Polysulfate Sodium, Prulifloxacin, Silodosin, Tanezumab.

Clinical trials & evidence

Clinical trials

Clinical trials: 31.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	15
PHASE3	7
PHASE4	4
PHASE2	3
PHASE2/PHASE3	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00194597	PHASE4	TERMINATED	Trial of Viagra’ in Men With Chronic Pelvic Pain Syndrome Type III
NCT00194636	PHASE4	SUSPENDED	Effectiveness of Sympathetic Plexus Block on Male Pelvic Pain (Prostatitis, Prostatodynia)
NCT01678911	PHASE4	TERMINATED	Efficacy of Gralise® for Chronic Pelvic Pain
NCT02246361	PHASE4	COMPLETED	Impact of Six Patient Information Leaflets (PIL) on Doctor Patient Communication
NCT06822751	PHASE3	NOT_YET_RECRUITING	FOsfomycin for Male Urinary Tract Infection
NCT00103402	PHASE3	COMPLETED	Trial to Compare Alfuzosin Versus Placebo in the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome
NCT00169585	PHASE3	COMPLETED	Levofloxacin For The Management Of Patients With Abnormal Prostate Specific Antigen (PSA)
NCT00236808	PHASE3	COMPLETED	A Study to Evaluate the Safety and Effectiveness of Levofloxacin Compared With Ciprofloxacin in Patients With Chronic Bacterial Prostatitis
NCT00260637	PHASE2/PHASE3	COMPLETED	Efficacy Study of Acupuncture to Relieve Symptoms of Chronic Prostatitis
NCT00277511	PHASE3	COMPLETED	Levofloxacin, Chronic Bacterial Prostatitis
NCT00402688	PHASE3	COMPLETED	An Effectiveness and Safety Study for Levofloxacin in Chronic Prostatitis
NCT00464373	PHASE3	TERMINATED	Botulinum Toxin Type A for the Treatment of Male Chronic Pelvic Pain Syndrome
NCT00236990	PHASE2	COMPLETED	An Effectiveness and Safety Study of ELMIRON (Pentosan Polysulfate Sodium) for the Treatment of Chronic Non-Bacterial Inflammation of the Prostate Gland
NCT00701311	PHASE2	COMPLETED	An Open-Label Study of CC-10004 for Chronic Prostatitis/Chronic Pelvic Pain Syndrome
NCT00775515	PHASE2	UNKNOWN	Laparoscopic Prostatectomy for Chronic Prostatitis
NCT00529386	PHASE1	TERMINATED	Botox for Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)
NCT06974175	Not specified	NOT_YET_RECRUITING	Effect of Graminex on Infertility Related to Male Accessory Glands Inflammation
NCT07324239	Not specified	NOT_YET_RECRUITING	TECAR Therapy on Pain and Quality of Life in Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome
NCT00675298	Not specified	COMPLETED	Linkage Analysis in Interstitial Cystitis
NCT00913315	Not specified	UNKNOWN	Efficacy Study of Tamsulosin and Tolterodine Treatment for Chronic Prostatitis
NCT01676857	Not specified	COMPLETED	Chemokine Mechanisms in Chronic Pelvic Pain
NCT01826617	Not specified	COMPLETED	Configuration of a New Prostate Disease Nomogram Predicting Prostate Biopsy Outcome
NCT01886547	Not specified	COMPLETED	2013 Annual National Digital Rectal Exam (DRE) Day Study
NCT01932645	Not specified	UNKNOWN	Etiology Study of Prostatitis
NCT03027076	Not specified	WITHDRAWN	Microbiome of Urologic Chronic Pelvic Pain Syndrome
NCT03720951	Not specified	UNKNOWN	Applying Pulsed Radiofrequency to the Pudendal Nerve Bilaterally Vs Its Application to Sacral Nerve Roots S2,3 and 4 Bilaterally in Chronic Prostatitis
NCT03879486	Not specified	COMPLETED	Infectious Outcomes of Povidone-iodine Rectal Cleansing Plus Formalin Disinfection of Needle During Prostate Biopsy
NCT03931538	Not specified	COMPLETED	Rapid Molecular Organism Identification and Mixed Flora Antibiotic Resistance Profiling (MixAR) Prospective Study
NCT05306314	Not specified	UNKNOWN	Retrospective Chart Review of Treataprost Added to Antibiotic Treatment in Patients With Chronic Prostatitis
NCT05732441	Not specified	UNKNOWN	Therapeutic Study of Prostatitis With Elevated PSA
NCT06968910	Not specified	COMPLETED	CBD-based Therapy to Attenuate Non-bacterial Prostatitis Symptoms

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
LEVOFLOXACIN ANHYDROUS	4	8
OFLOXACIN	4	4
TOLTERODINE	4	4
ALFUZOSIN	4	3
APREMILAST	4	1
BOTULINUM TOXIN TYPE A	4	1
GABAPENTIN	4	1
PENTOSAN POLYSULFATE SODIUM	4	1